Bastiaan Sallevelt

85 Evaluation of clarity of the STOPP/START criteria - SI Table SI1.1. Continued. STOPP Action Clarity rating Condition Clarity rating Explanation Clarity rating D12 Phenothiazines 75% as first-line treatment, 83% since safer and more efficacious alternatives exist (phenothiazines are sedative, have significant anti-muscarinic toxicity in older people, with the exception of prochlorperazine for nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an antiemetic in palliative care). 92% D13 Levodopa or dopamine agonists 83% for benign essential tremor 100% (no evidence of efficacy) 83% D14 First-generation antihistamines 17% [users of…first-generation antihistamines] 33% (safer, less toxic antihistamines now widely available). 75% E E1 Digoxin at a long-term dose greater than 125µg/day 100% if eGFR < 30 ml/min/1.73m2 83% (risk of digoxin toxicity if plasma levels not measured). 67% E2 Direct thrombin inhibitors (e.g. dabigatran) 58% if eGFR < 30 ml/min/1.73m2 100% (risk of bleeding) 67% E3 Factor Xa inhibitors (e.g. rivaroxaban, apixaban) 58% if eGFR < 15 ml/min/1.73m2 100% (risk of bleeding) 67% E4 NSAID’s 42% if eGFR < 50 ml/min/1.73m2 100% (risk of deterioration in renal function). 75% 2